Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1948-1953

  Ono, A ^a   Kenmotsu, H ^a   Watanabe, M ^a   Serizawa, M ^a   Mori, K ^a   Imai, H ^a   Taira, T ^a   Naito, T ^a   Murakami, H ^a   Nakajima, T ^a   Ohde, Y ^a   Endo, M ^a   Yamamoto, N ^b   Koh, Y ^a   Takahashi, T ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

EGFR mutation burden; EGFR TKI; L858R; lung adenocarcinoma; mutant allele frequency; tumor heterogeneity

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADENOCARCINOMA; AGED; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84930586776     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu251     Document Type: Article

References (26)

1. Lynch, T.J., Bell, D.W., Sordella, R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.
2. Mitsudomi, T., Morita, S., Yatabe, Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 (2010), 121–128.
3. Faber, A.C., Corcoran, R.B., Ebi, H., et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1 (2011), 352–365.
4. Tanaka, K., Hata, A., Kaji, R., et al. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol 8 (2013), 892–898.
5. Yu, H.A., Arcila, M.E., Hellmann, M.D., et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25 (2014), 423–428.
6. Wu, J.Y., Wu, S.G., Yang, C.H., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14 (2008), 4877–4882.
7. Taniguchi, K., Okami, J., Kodama, K., et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99 (2008), 929–935.
8. Zhou, Q., Zhang, X.C., Chen, Z.H., et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 29 (2011), 3316–3321.
9. Eisenhauser, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
10. Marchetti, A., Felicioni, L., Buttitta, F., Assessing EGFR mutations. N Engl J Med 354 (2006), 526–528.
11. Pao, W., Ladanyi, M., Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13 (2007), 4954–4955.
12. Han, J.Y., Park, K., Kim, S.W., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30 (2012), 1122–1128.
13. Yatabe, Y., Hida, T., Horio, Y., et al. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 8 (2006), 335–341.
14. Nagai, Y., Miyazawa, H., Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65 (2005), 7276–7282.
15. Newton, C.R., Graham, A., Heptinstall, L.E., et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17 (1989), 2503–2516.
16. Ronaghi, M., Uhlén, M., Nyrén, P., A sequencing method based on real-time pyrophosphate. Science 281 (1998), 363–365.
17. Dufort, S., Richard, M.J., Lantuejoul, S., et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res, 30, 2011, 57.
18. Tougeron, D., Lecomte, T., Pagès, J.C., et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 24 (2013), 1267–1273.
19. Weidlich, S., Walsh, K., Crowther, D., et al. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer 105 (2011), 246–254.
20. Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137 (2013), 828–860.
21. Yatabe, Y., Matsuo, K., Mitsudomi, T., Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29 (2011), 2972–2977.
22. Fujita, Y., Suda, K., Kimura, H., et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 7 (2012), 1640–1644.
23. Taniguchi, K., Uchida, J., Nishino, K., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17 (2011), 7808–7815.
24. Thomas, R.K., Nickerson, E., Simons, J.F., et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12 (2006), 852–855.
25. Arcila, M.E., Oxnard, G.R., Nafa, K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17 (2011), 1169–1180.
26. Querings, S., Altmüller, J., Ansén, S., et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One, 6, 2011, e19601.